A top influencer in China has announced a halt to updates of his social media account for the sake of his health, arousing significant nationwide attention. The announcement comes after the sudden deaths of a slew of online celebrities at a young age due to work pressure, the Liaoshen Evening News reported. Wang Bowen, who uses the handle @dalianlaoshiwangbowen on social media and has amassed more than 20 million followers, said in mid-May that he would stop releasing videos for an “indefinite duration”. Advertisement “Intense content creation for the past 13 years has overdrafted my physical and mental health. I have got health problems like tinnitus, depression, anxiety and heart disease,” Wang said in his latest video. Wang Bowen, above, produces zany content based in an urban setting. Photo: Baidu The blogger, who was born in the 1990s and lives in Dalian, Liaoning province, northeastern China, said he would feel sick and anxious whenever he saw a camera or face questions about when he would release new videos.

While Canada may be clinging to fossil fuels, much of the world is moving on Casual international observers would be forgiven for assuming Canada is in the comforting hands of a climate champ. After all, while climate policy rollbacks reign supreme in Donald Trump’s America, Canada is now led by a man who, while serving as governor of the Bank of England, delivered a celebrated 2015 speech, “ Breaking the tragedy of the horizon ”, warning the global investment community of the financial risks of climate change; who went on to serve as UN special envoy for climate action and finance ; and whose 2022 book Value(s) had much to say about the “existential threat” of climate change. A man who recently dazzled the world with his Davos speech on how middle powers can stand up to global bullies. Look, we get it. Next to the US president, Carney seems so debonair, thoughtful and calm – a lifeline of stability in a volatile new world. Seth Klein is a Canadian climate writer and activist, author of the book A Good War: Mobilizing Canada for the Climate Emergency , and former team lead of the Climate Emergency Unit . His newsletter can be found here . Continue reading...

Maths was never my thing. I quite enjoyed it at O-level, to the extent that I chose to do it at A-level. As early as the first week of the A-level course, however, it became abundantly clear that the subject was quite beyond me. I simply couldn’t make head or tail of what the teacher was on about. Looking around at the rest of the class quietly getting on with it, I remember wondering if there had been some primer course over the summer that everyone but me had attended. I just didn’t get it. There didn’t seem to be any certainties any more, rarely anything so straightforward as a right or wrong answer. There were enough grey areas in my other subjects – English and history. From my maths I wanted certainty, objective truth, which as far as I could see wasn’t part of it any more. Where were the times tables, for example? I’d nailed those good and proper at a very early age. In ascending order of difficulty I would rate them as follows: two, 10, five, 11, three, four, six, eight, seven and 12. You’ll notice that the nine times table does not feature on this list. Why? Well, I found it too easy. It was my speciality. But that’s because I was cheating – or so it felt – as someone had showed me a quick trick with which to nail the nines, as it were. For this reason, I was fascinated to read that in an analysis of times tables answers by primary school children, it was ones that involved the number nine that were most often wrong. They’re not the only ones. When the then school standards minister Nick Gibb announced the rollout of national multiplication tests in 2018, he refused to attempt 8x9 on ITV’s Good Morning Britain. What’s the matter with everyone? Nines are easy! If you kind of cheat, like me. What you do is this. Hold your hands up, palms facing you. If it’s 8x9 you’re interested in, just fold down the eighth digit from the left, which will be the middle finger of your right hand. Now count the number of digits still standing to the left of the one you’ve fold...

okies3D/iStock via Getty Images Market review and outlook The Bloomberg 1-3 Year Government/Credit Index returned 0.28% in Q1, its lowest quarterly return since Q4 2024 (-0.02%). Through the first two months of the year, the index returned 0.75% as economic data remained broadly resilient despite concerns around the February sell-off in software stocks, a key tariff decision by the Supreme Court and the growing drumbeat of war in the Middle East. The US and Israel launched combat operations against Iran on February 28, and the markets spent most of March reeling from the ongoing conflict, resulting in Brent crude oil experiencing its biggest quarterly increase since the Gulf War in 1990. While one normally thinks of a flight-to-quality trade as a rally in Treasury yields as investors move away from risk assets to safer alternatives, this was not the case in March as rates pushed higher across the curve. The Fed held rates steady at the March 18 meeting and avoided any kind of hints about the future path of rates. Despite concerns around the impact of higher energy prices on inflation due to the conflict, no participants viewed a 2026 hike as appropriate at this time. At his press conference, Chairman Jerome Powell alleviated some concern around the leadership of the Federal Reserve, stating that he would remain as chair pro tempore until his replacement is confirmed. Updates by sector Treasury The entire Treasury yield curve pushed higher in Q1, with most of the shift taking place in March after combat operations began in the Middle East. The 2-year Treasury yield climbed 41.8 basis points (BPs) in March, marking its biggest monthly move since October 2024 when ongoing strength in economic news had investors reconsidering rate cut expectations. The dramatic shift in March was more than enough to offset some of the compression in yield during the first two months of the year, resulting in an increase of 32 bps during Q1. But the trend higher impacted the entire curve...

Elon Musk ’s SpaceX pulled back the curtain on a business empire that has racked up ballooning losses and debt after acquiring a cash-hungry startup, and pumping billions of dollars into futuristic endeavors ranging from AI to a Mars rocket. The prospectus that SpaceX filed Wednesday for an IPO of unprecedented size boiled down to a well-worn strategy that entrepreneurs commonly hawk up and down Wall Street: in order to make money, we need to spend money. And nowhere are the outlays larger than in space and artificial intelligence. “The big takeaway for me is that SpaceX is now an AI company,” said Chad Anderson , an early SpaceX investor and founder of Space Capital. Musk is seeking to pull off the unprecedented feat of achieving a $2 trillion valuation from the outset, an audacious plan that’s set to transform both the public and private markets if it succeeds. At the same time, the prospectus lays bare concerns over whether private companies with limited financial disclosures and largely illiquid shares are reaching unjustified valuations in venture capital-led funding rounds. “Investors aren’t paying for today’s business, they’re paying for the platform that owns the next 50 years of orbital infrastructure,” Anderson said. The company’s future projections, even when championed by a celebrity figure like Musk, are nothing short of extreme. SpaceX states that their total addressable market, or maximum revenue ceiling, is $28.5 trillion, by far the largest in history, according to the filing. Nearly all of that would come from AI, with space making up $370 billion and Starlink-based connectivity $1.6 trillion. Mike Alves, founder and fund manager of VIDA Vision Fund and early investor in SpaceX, said it’s a “shocker” how aggressively the company is pitching its AI capabilities. “For a rocket company, that’s wild,” Alves said. Then again, buried in a filing of over hundreds of pages were glimmers of financial promise. The company reported $18.7 billion in 2025 reven...

Amid allegations of abuse on Epstein's 'Zorro Ranch,' New Mexico opens new probes toggle caption Roberto E. Rosales/Getty Images North America On International Women's Day in March, hundreds of protesters caravanned out to a spot in the desert outside of Santa Fe. Their gathering place was a ranch in the high desert of New Mexico that once belonged to the late financier and sex offender Jeffrey Epstein. One of the demonstrators at the rally at the ranch was Virginia Giuffre's brother, Sky Roberts. Giuffre, who died by suicide in 2025, was one of Epstein's most prominent accusers and said she had been sexually abused at the ranch . Roberts referred to two investigations recently started by New Mexico officials. toggle caption Daniel Montaño/KUNM "This is what we need to see more of state by state. I think New Mexico is taking the first initiative. I think the people of New Mexico are demanding answers, they're demanding justice," Roberts said. "It starts here and there's so much more that we can continue to fight for." Sponsor Message In addition to his more well-known properties, including his Manhattan mansion and his private Caribbean island, Epstein owned this property, known as the Zorro Ranch. It housed a mansion, an airstrip and 10,000 acres of scrubland. For decades there have been suspicions – some noted by officials – and even talk-radio chatter, of crimes at the ranch, including claims bodies are buried on the grounds. Connections have been drawn to several prominent figures, and court documents place some of the earliest accusations of abuse at the ranch . Now New Mexico officials say they're seeking the truth of what happened there with the two investigations. The state's attorney general's office announced in February it was re-opening an old investigation that was closed in 2019 at the request of federal prosecutors in New York. New Mexico's justice department went on to perform a search of the vast property with search and rescue dogs. toggle caption ...

is a senior editor and founding member of The Verge who covers gadgets, games, and toys. He spent 15 years editing the likes of CNET, Gizmodo, and Engadget. Posts from this author will be added to your daily email digest and your homepage feed. Bambu Lab makes the best, most accessible 3D printers yet, but that reputation is suddenly under siege. It all started when Paweł Jarczak received a private message from the company on Reddit asking him to delete his code. Now the 3D printing community is lining up behind Jarczak to fund a war against Bambu — and the future of 3D printers could be at stake. Jarczak is a developer who shared a way to let people remote control their Bambu printers without using Bambu software. But Bambu wanted to lock down its system, despite relying on open-source code. That provoked a furious coalition of open-source advocates and YouTubers to respond. “I’ll put up $10,000 to teach bambu labs a lesson,” declared consumer rights advocate Louis Rossmann, pledging to help defend Jarczak in court. “I’m never buying a Bambu Lab 3D printer again,” stated maker Jeff Geerling, adding that he’d gladly chip in too. (He’s changed the YouTube title since.) “Go fuck yourself, Bambu,” wrote GamersNexus, pledging to commit $10,000 as well. (It’s also halting previously unannounced plans to buy $150,000 of Bambu hardware for a 3D printing project, editor-in-chief Steve Burke tells The Verge.) “Go ahead, Bambu: Sue us,” taunts GamersNexus, which has also begun investigating scattered reports of a Bambu printer catching fire. If that wasn’t enough, Rossmann, Burke, and thousands of other open-source advocates are daring Bambu to take legal action — they’re each forking the code Bambu was hoping to suppress. As of Monday, so is the Software Freedom Conservancy, which is now hosting an entire project to reverse engineer Bambu’s code and says it will serve as a Bambu watchdog. “They’re bad actors, straight-up, and the community should do whatever we can,” Bradley...

Researchers say the Trump administration is finding new ways to punish science toggle caption Jodi Hilton for NPR Standing in his laboratory, Harvard professor Sean Eddy gazes at a row of vacant work stations. More than a year ago, this lab was filled with over a dozen researchers. On a given day they might be working independently on analyzing genomic sequencing or gathered around the group table, drinking coffee and helping each other troubleshoot questions about genomic data from different species. Now, after his funding was terminated under the Trump administration, the computer screens are gone and the room is silent. He's one of the last people left. " Seeing these labs empty — this is not the way it's supposed to be," he says. "This was a very vibrant lab." Sponsor Message Eddy is a computational biologist. He has devoted his career to one fundamental question. " I'm really interested in the origin of life," he says. "I want to know where it all came from." He and his colleagues spent years developing software that could be used to seek out an answer. Scientists around the world now use the tools his team created to compare DNA and protein sequences, identify genes, and predict what they do. Their work underpins countless studies, including research related to cancer and neurodevelopmental disorders. It's hard to quantify how much modern science relies on what his team built. Eddy describes its use as being as ubiquitous as microscopes or pipettes. "It's very affirming for me to pick up sort of semi-random papers in the literature in fields that I care about and see them using our software over and over again," he says. When the lab was designed more than a decade ago, he worked closely with an architect. On the wall are pictures of animals. His daughter, who was 12 at the time, stenciled them for him. Mixed in with pictures of mice and fish are laboratory creatures. "There's a bacterial virus called T4 that I did my thesis on," he says, pointing to the wall....

Quarterly Total Revenues Reached RMB25,532.7 Million (US$3,701.5 Million)i Quarterly Vehicle Deliveries Were 83,465 Units SHANGHAI, China, May 21, 2026 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the global smart electric vehicle market, today announced its unaudited financial results for the first quarter ended March 31, 2026. Operating Highlights for the First Quarter of 2026 Vehicle deliveries were 83,465 in the first quarter of 2026, representing an increase of 98.3% from the first quarter of 2025, and a decrease of 33.1% from the fourth quarter of 2025. The deliveries consisted of 58,543 vehicles from NIO brand, 13,339 vehicles from ONVO brand, and 11,583 vehicles from FIREFLY brand. Key Operating Results 2026 Q1 2025 Q4 2025 Q3 2025 Q2 Deliveries 83,465 124,807 87,071 72,056 2025 Q1 2024 Q4 2024 Q3 2024 Q2 Deliveries 42,094 72,689 61,855 57,373 Financial Highlights for the First Quarter of 2026 Vehicle sales were RMB22,783.7 million (US$3,302.9 million) in the first quarter of 2026, representing an increase of 129.2% from the first quarter of 2025 and a decrease of 27.9% from the fourth quarter of 2025. were RMB22,783.7 million (US$3,302.9 million) in the first quarter of 2026, representing an increase of 129.2% from the first quarter of 2025 and a decrease of 27.9% from the fourth quarter of 2025. Vehicle margin ii was 18.8% in the first quarter of 2026, compared with 10.2% in the first quarter of 2025 and 18.1% in the fourth quarter of 2025. was 18.8% in the first quarter of 2026, compared with 10.2% in the first quarter of 2025 and 18.1% in the fourth quarter of 2025. Total revenues were RMB25,532.7 million (US$3,701.5 million) in the first quarter of 2026, representing an increase of 112.2% from the first quarter of 2025 and a decrease of 26.3% from the fourth quarter of 2025. were RMB25,532.7 million (US$3,701.5 million) in the first quarter of 2026, representing an increase o...

"The FRUSICA-2 trial results provided compelling evidence that the sintilimab and fruquintinib combination could play a meaningful role in shaping second-line treatment strategies for advanced renal cell carcinoma," said Professor Zhisong He of Peking University First Hospital and co-lead Principal Investigator of the FRUSICA-2 study. "We are optimistic about the clinical implications of this approval as we strive to provide effective treatment options for patients." "The rapid advancements in targeted therapies, immunotherapies, and their combination regimens have led to a significant evolution in the treatment landscape for advanced renal cell carcinoma. Optimizing the selection of treatment for individual patients is a key focus of clinical interest," said Professor Dingwei Ye of Fudan University Shanghai Cancer Center and co-lead Principal Investigator of the FRUSICA-2 study. "The approval of the sintilimab and fruquintinib combination underscores its potential to address the pressing medical needs of patients with this challenging disease." The approval is supported by data from FRUSICA-2, a randomized, open-label, active-controlled registration study evaluating the efficacy and safety of sintilimab in combination with fruquintinib versus axitinib or everolimus monotherapy for the second-line treatment of patients with locally advanced or metastatic renal cell carcinoma. The study met its primary endpoint of progression free survival (PFS) as assessed by blinded independent central review (BICR). SAN FRANCISCO and SUZHOU, China, May 21, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and HUTCHMED (China) Limited (" HUTCHMED ") (Nasdaq/AIM:HCM; HKEX:13), today jointly announce that the New Drug Application (NDA) for the combination of TYVYT ® (sintilima...

“This approval reaffirms our deep commitment to delivering innovative therapies to patients facing advanced renal cell carcinoma in China, where second-line treatment options remain limited,” said Mr Johnny Cheng, Acting Chief Executive Officer and Chief Financial Officer of HUTCHMED . “We are excited to continue pushing the boundaries of our research — across monotherapies, combination strategies, and exciting new platforms such as our ATTC technology — to unlock even greater therapeutic potential across various tumor types, ultimately providing more impactful and transformative solutions to patients.” “The FRUSICA-2 trial results provided compelling evidence that the fruquintinib and sintilimab combination could play a meaningful role in shaping second-line treatment strategies for advanced renal cell carcinoma,” said Professor Zhisong He of Peking University First Hospital and co-lead Principal Investigator of the FRUSICA-2 study. “We are optimistic about the clinical implications of this approval as we strive to provide effective treatment options for patients.” “The rapid advancements in targeted therapies, immunotherapies, and their combination regimens have led to a significant evolution in the treatment landscape for advanced renal cell carcinoma. Optimizing the selection of treatment for individual patients is a key focus of clinical interest,” said Professor Dingwei Ye of Fudan University Shanghai Cancer Center and co-lead Principal Investigator of the FRUSICA-2 study. “The approval of the fruquintinib and sintilimab combination underscores its potential to address the pressing medical needs of patients with this challenging disease.” The approval is supported by data from FRUSICA-2, a randomized, open-label, active-controlled registration study evaluating the efficacy and safety of fruquintinib in combination with sintilimab versus axitinib or everolimus monotherapy for the second-line treatment of patients with locally advanced or metastatic renal cell c...

Data from the all-oral combination of BeOne’s foundational BCL2 inhibitor sonrotoclax plus zanubrutinib (ZS) in CLL , which demonstrated deep responses, unprecedented speed to undetectable MRD, and durable remissions and a generally well-tolerated safety profile. These data reinforce the potential for a next-generation, time-limited approach designed to deliver long-term outcomes without compromising durability or safety. Data will be presented as a poster at ASCO 2026 and an oral presentation at EHA 2026. Oral presentation at EHA 2026 of updated data of BeOne’s foundational BTK degrader – BGB-16673 – in patients with R/R CLL , demonstrating promising and durable activity and a manageable safety profile. An additional poster will be shared featuring never-before-presented data of BGB-16673 in BTK-naïve patients. BGB-16673 is the most advanced BTK degrader in the clinic, with more than 1,100 patients dosed. A subgroup analysis of SEQUOIA, which includes one of the largest and longest-followed cohorts of patients aged ≥80 years ever reported in a Phase 3 CLL study , showing that age did not limit benefit. Data will be presented at EHA 2026. New results from the SEQUOIA trial with 78 months follow-up reinforce BRUKINSA ® (zanubrutinib) as the foundational BTK inhibitor in CLL, with durable disease control that continues to raise expectations for what patients and physicians should expect from first-line therapy over the long term. Data will be presented at both ASCO and EHA. "Seventy-eight-month follow-up data from SEQUOIA underscore what it truly takes to lead in CLL over the long term: long-term efficacy, ability for sequencing treatments, and confidence in first-line treatment decisions. Building on that leadership, we’re excited to be rapidly advancing the next generation of medicines, including sonrotoclax-based combinations and our BTK degrader BGB-16673, which are designed to extend what is possible for patients across lines of therapy." At ASCO and EHA 2026, Be...

0:00 spk_0 All right. Welcome to a new episode of Power Players. I'm your host, Brian Sazi, and we are taping this episode at the Milken Institute conference in Los Angeles, and I'm, it's a real honor to welcome on my next guest to this episode, uh, artist, composer, producer, entrepreneur, Wyclef. It's so good to see you. Like, it's a real honor to have you here, seriously, I appreciate it. Um you, man. What bringsyou to Milken? 0:22 spk_1 Um, well, first of all, thank you to Milke for having me. And I would say in the past, uh, 30 years, um, I started off at the Fugees, and I think a lot of times people look at the music and behind the music is the engineering. So, as an engineer, I started with hardware, uh, software conversion, uh, streaming.To AI Music, uh, I've been progressive in the process, I've been part of a few companies, one of them being Open Wave. I'm, uh, I also, I'm also a consultant for Google DeepMind.Um, division, um, so just I'm here as we move towards the future. The, the future of music is being shaped differently to talk about like how I see us moving forward in the next 10 years. 1:08 spk_0 The lasttime I saw you, it was maybe 2 or 3 years at Davos at a Google event. Um, that's why I was so excited to see you on the list for this one. You came and you played, I think you played a guitar, but then you talked about how AI was changing.The music industry and now fast forward 2+ years we're here. Like what changes are you seeing? 1:28 spk_1 Well, the changes, one of the main changes we're seeing is accessibility on how easier it is to do music with the two. the other, uh, trend that we're seeing is, uh, the, the music AI, uh, gets refused a lot by super creators.But the average norm person like my wife is the most amazing thing to her. So, um, so, and, and now it's, it's normality, right? Um, to do music, you have to have these studios, you have to have a sense of, um, you know, how these notes are going, how these beats are going now, whatever ...

The 2027 Social Security cost-of-living adjustment (COLA) wasn't supposed to be anything special, according to the earliest forecasts. The Senior Citizens League (TSCL), a nonpartisan senior group, initially predicted that the COLA would fall somewhere between 2.5% and 2.8%. But rising inflation has begun to change that picture. Some are now wondering if the 2027 COLA will exceed 4%. While we can't know for sure until the official announcement in October, recent projections give us a rough idea of where Social Security benefits could be headed next year. The 2027 COLA is likely to be higher than previously expected TSCL's 2027 Social Security COLA prediction rose from 2.8% in April 2026 to 3.9% in May 2026. A 1.1 percentage point increase in a single month is unusual, and it reflects concerns about rising inflation. The Consumer Price Index used to calculate Social Security COLAs revealed that inflation rose by 3.8% in April 2026, up from 3.3% the month before. This has largely been driven by higher gas prices, though other costs have increased as well. If inflation continues to rise, a 2027 COLA of 4% or more is a real possibility. A 4% increase would add $83 to the $2,081 average retirement benefit as of April 2026. That would give the typical senior nearly $1,000 more throughout the year, and some people may see a much larger increase if they're currently receiving an above-average benefit. The reality of a 4% Social Security COLA While a 4% Social Security COLA might sound like an improvement over the 2.8% boost seniors saw this year, it's important to remember that larger COLAs appear alongside rising living costs. Regardless of the size of the 2027 COLA, it's unlikely to drastically change your quality of life. You'll still need personal savings and possibly a job to cover what your Social Security benefits won't. If you're struggling to make ends meet, you may need to look into other government benefits as well to help you with your essential costs, like food...

China's Manus founders seek $1 billion to undo Meta takeover, Bloomberg News reports Reuters

近日，国家药品监督管理局通过优先审评审批程序批准Janssen-Cilag International NV申报的尼卡利单抗注射液（商品名：安力威）上市，该品种与常规治疗药物联合用于治疗抗乙酰胆碱受体(AChR)抗体或抗肌肉特异性酪氨酸激酶 (MuSK) 抗体阳性的成人和12岁及以上青少年全身型重症肌无力(gMG)患者。该品种的上市为相关患者提供了新的治疗选择。(国家药品监督管理局)

格隆汇5月21日｜5月21日，摩根大通第二十二届全球中国峰会上海举行，摩根大通中国股票策略师张晓宁出席会议并发表主题演讲。对于中国股票市场，摩根大通中国股票策略师张晓宁维持积极乐观的判断。摩根大通预计，MSCI中国指数年底基准情形目标点位为100点，乐观情形为120点，悲观情形为80点；沪深300指数年底基准情形目标点位为5200点，乐观情形为6000点，悲观情形为4200点。“市场仍具备可观的上行空间，核心支撑来自流动性的充裕与业绩预期的向好‘双重共振’。”张晓宁说。

Aragen Life Sciences Ltd. , a contract research and manufacturing firm, is considering an initial public offering in Mumbai that could raise as much as $300 million, according to people familiar with the matter. The Hyderabad-based company backed by Goldman Sachs Group and Quadria Capital has engaged Axis Capital Ltd. , Citigroup Inc, Goldman Sachs Group Inc. and JM Financial Ltd. to advise on the planned share sale, the people said, asking not to be identified because the discussions are private. The IPO is expected to comprise a mix of primary and secondary share sales and could take place as early as the final quarter of this year, the people said. Deliberations are ongoing and details including the size and timing of the offering could still change. Representatives for Aragen and the banks did not immediately respond to requests for comment. Aragen secured a $100 million investment from private equity firm Quadria Capital in January 2024 at a valuation of about $1.4 billion. Goldman Sachs Asset Management acquired a significant minority stake in the company in 2021 through the purchase of shares held by ChrysCapital and other investors. India’s contract research, development and manufacturing organization, or CRDMO, industry is expected to expand to as much as $25 billion by 2035 from about $3 billion to $3.5 billion currently, according to a report by Boston Consulting Group. Aragen provides contract research, development and manufacturing services across the drug development cycle, with a focus on early-stage discovery and development of new molecular entities. The company operates eight global sites and employs more than 5,000 people, according to its website .

Tesla Background Through a thorough examination of Tesla, we can discern the following trends: Debt To Equity Ratio The debt-to-equity (D/E) ratio helps evaluate the capital structure and financial leverage of a company. Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making. By evaluating Tesla against its top 4 peers in terms of the Debt-to-Equity ratio, the following observations arise: Tesla exhibits a stronger financial position compared to its top 4 peers in the sector, as indicated by its lower debt-to-equity ratio of 0.19 . This suggests that the company has a more favorable balance between debt and equity, which can be seen as a positive aspect for investors. Key Takeaways For Tesla, its high PE, PB, and PS ratios suggest that the stock is relatively expensive compared to its peers in the Automobiles industry. The low ROE indicates that Tesla's profitability is lower than its industry counterparts. However, the high EBITDA, gross profit, and revenue growth signify strong operational performance and growth potential for Tesla within the industry sector. This article was generated by Benzinga's automated content engine and reviewed by an editor.

Micron Technology Background Micron is one of the largest semiconductor companies in the world, specializing in memory and storage chips. Its primary revenue stream comes from dynamic random access memory, or DRAM, and it also has minority exposure to not-and or NAND, flash chips. Micron serves a global customer base, selling chips into data centers, mobile phones, consumer electronics, and industrial and automotive applications. The firm is vertically integrated. Through an analysis of Micron Technology, we can infer the following trends: Debt To Equity Ratio The debt-to-equity (D/E) ratio indicates the proportion of debt and equity used by a company to finance its assets and operations. Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making. When examining Micron Technology in comparison to its top 4 peers with respect to the Debt-to-Equity ratio, the following information becomes apparent: When comparing the debt-to-equity ratio, Micron Technology is in a stronger financial position compared to its top 4 peers. The company has a lower level of debt relative to its equity, indicating a more favorable balance between the two with a lower debt-to-equity ratio of 0.15. Key Takeaways For Micron Technology, the PE, PB, and PS ratios are all low compared to industry peers, indicating potential undervaluation. On the other hand, the high ROE, EBITDA, gross profit, and revenue growth suggest strong financial performance and growth prospects relative to competitors in the Semiconductors & Semiconductor Equipment industry. This article was generated by Benzinga's automated content engine and reviewed by an editor.

美国 强生 公司21日宣布，其用于治疗全身型重症肌无力的药物尼卡利单抗（nipocalimab）已正式获得中国国家药品监督管理局批准。该药物的适用人群为12岁及以上的相关患者群体。 全身型重症肌无力是一种免疫相关的神经肌肉疾病，临床主要表现为眼部、口腔、咽喉及四肢等部位的骨骼肌无力。公开资料显示，强生公司于2020年通过斥资65亿美元收购Momenta公司，从而获取该药物的核心管线。此前，该药物已在美国、巴西及日本等多个海外市场获批上市。业界普遍预期，该药物具有巨大的市场潜力，有望为企业带来显著的营收增长。 目前，强生方面暂未就该药物在华的具体定价及上市时间表作出回应。在当前的中国医药市场中，包括翰森制药、再鼎医药及Argenx等企业研发的全身型重症肌无力治疗药物已先后获批上市。 责任编辑：龙运翔

核心要点 超威（ AMD ）宣布，将在台湾半导体及人工智能产业生态累计 投资超 100 亿美元 。 此次投资侧重携手本土企业，攻坚下一代人工智能基础设施所需的 芯片封装与芯片制造 技术。 依托全球最大晶圆代工厂 台积电 ，中国台湾稳居全球半导体产业核心地位。 2026 年 1 月 5 日，美国内华达州拉斯维加斯消费电子展现场，超威董事长兼首席执行官苏姿丰出席活动。 超威公司于周四官宣，将投入超 100 亿美元深耕中国台湾半导体与人工智能全产业链，助力提升芯片产能与产品性能。 坐拥全球第一大芯片代工厂台积电，中国台湾成为全球半导体产业核心枢纽，台积电同时为英伟达、 苹果 等全球顶尖企业代工生产芯片。 伴随全球人工智能基础设施持续巨额投入，超威股价年内已实现翻倍，公司正全力向行业对手英伟达发起冲击；英伟达此前已于周三公布业绩大增的亮眼财报。 超威在官方公告中表示：“公司将联合台湾及全球战略合作伙伴，持续突破前沿芯片设计、先进封装与制造工艺，助力人工智能系统实现更高性能、更高能效与更快落地部署。” 本次投资重点围绕下一代人工智能基建所需的芯片封装、制造领域展开深度产业合作。 目前超威已携手台湾日月光、彩晶科技等企业，共同研发芯片互联集成技术，以此提升芯片整体运行效能。 相关技术研发成果，将为超威 2026 年下半年正式推出赫利俄斯人工智能服务器系统 提供技术支撑。 此外，圣米纳、纬颖、纬创、英业达等企业，也已确定参与这款人工智能服务器产品的联合研发与量产工作。 责任编辑：郭明煜

Investment House LLC lowered its position in shares of Intel Corporation (NASDAQ:INTC - Free Report) by 90.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 13,802 shares of the chip maker's stock after selling 136,194 shares during the quarter. Investment House LLC's holdings in Intel were worth $509,000 as of its most recent filing with the Securities & Exchange Commission. Several other hedge funds have also recently modified their holdings of the company. Winch Advisory Services LLC lifted its position in shares of Intel by 28.3% during the 4th quarter. Winch Advisory Services LLC now owns 966 shares of the chip maker's stock worth $36,000 after buying an additional 213 shares in the last quarter. Focus Financial Network Inc. lifted its position in shares of Intel by 2.1% during the 4th quarter. Focus Financial Network Inc. now owns 10,788 shares of the chip maker's stock worth $398,000 after buying an additional 223 shares in the last quarter. Successful Portfolios LLC lifted its position in shares of Intel by 2.6% during the 4th quarter. Successful Portfolios LLC now owns 8,715 shares of the chip maker's stock worth $322,000 after buying an additional 223 shares in the last quarter. Orca Investment Management LLC lifted its position in shares of Intel by 0.5% during the 4th quarter. Orca Investment Management LLC now owns 50,697 shares of the chip maker's stock worth $1,871,000 after buying an additional 229 shares in the last quarter. Finally, Jeppson Wealth Management LLC lifted its position in shares of Intel by 1.1% during the 4th quarter. Jeppson Wealth Management LLC now owns 21,236 shares of the chip maker's stock worth $784,000 after buying an additional 229 shares in the last quarter. Institutional investors own 64.53% of the company's stock. Get Intel alerts: Sign Up Insiders Place Their Bets In related news, EVP Boise April Miller sold 40,256 shar...

Intrust Bank NA trimmed its holdings in shares of Intel Corporation (NASDAQ:INTC - Free Report) by 25.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,662 shares of the chip maker's stock after selling 10,301 shares during the period. Intrust Bank NA's holdings in Intel were worth $1,131,000 as of its most recent SEC filing. Other institutional investors and hedge funds also recently bought and sold shares of the company. Legacy Bridge LLC bought a new position in shares of Intel in the fourth quarter valued at about $26,000. Raleigh Capital Management Inc. bought a new stake in Intel during the 4th quarter worth about $29,000. HighMark Wealth Management LLC grew its holdings in Intel by 177.7% during the 4th quarter. HighMark Wealth Management LLC now owns 886 shares of the chip maker's stock worth $33,000 after acquiring an additional 567 shares during the last quarter. Provenance Wealth Advisors LLC increased its position in Intel by 89.2% in the 3rd quarter. Provenance Wealth Advisors LLC now owns 946 shares of the chip maker's stock valued at $32,000 after acquiring an additional 446 shares in the last quarter. Finally, Winch Advisory Services LLC raised its stake in shares of Intel by 28.3% in the fourth quarter. Winch Advisory Services LLC now owns 966 shares of the chip maker's stock worth $36,000 after acquiring an additional 213 shares during the last quarter. Institutional investors and hedge funds own 64.53% of the company's stock. Get Intel alerts: Sign Up Key Intel News Here are the key news stories impacting Intel this week: Positive Sentiment: Intel is benefiting from a broad chip-sector rebound ahead of Nvidia’s earnings, with traders betting the AI infrastructure boom will keep lifting semiconductor stocks. This helped Intel snap a recent losing streak and attract strong volume. Intel is benefiting from a broad chip-sector rebound ahead of Nvidia’s e...

Investment House LLC Sells 136,194 Shares of Intel Corporation $INTC MarketBeat

Investment House LLC lessened its position in Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM - Free Report) by 75.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,221 shares of the semiconductor company's stock after selling 9,968 shares during the quarter. Investment House LLC's holdings in Taiwan Semiconductor Manufacturing were worth $979,000 at the end of the most recent reporting period. Several other institutional investors and hedge funds have also recently modified their holdings of TSM. Shannon River Fund Management LLC purchased a new stake in Taiwan Semiconductor Manufacturing during the 3rd quarter worth about $2,430,000. Vanguard Personalized Indexing Management LLC lifted its position in Taiwan Semiconductor Manufacturing by 9.4% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 101,876 shares of the semiconductor company's stock worth $28,470,000 after acquiring an additional 8,738 shares during the period. Hantz Financial Services Inc. lifted its holdings in shares of Taiwan Semiconductor Manufacturing by 28.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 37,216 shares of the semiconductor company's stock valued at $10,394,000 after buying an additional 8,284 shares during the period. Meridian Wealth Management LLC raised its holdings in Taiwan Semiconductor Manufacturing by 27.9% during the fourth quarter. Meridian Wealth Management LLC now owns 65,974 shares of the semiconductor company's stock worth $20,049,000 after purchasing an additional 14,406 shares during the last quarter. Finally, Hollencrest Capital Management increased its position in Taiwan Semiconductor Manufacturing by 125.3% during the third quarter. Hollencrest Capital Management now owns 5,216 shares of the semiconductor company's stock worth $1,457,000 after buying an additional 2,901 shares in the last quarter. Hedge funds and other institutional inves...

近日，网络上出现题为《2026年度中央储备棉轮出投放内部实施工作计划》的虚假信息，引发行业关注。据中国棉花协会核实，国家有关部门和协会从未制定过相关文件，所传文件内容纯属捏造。对于故意捏造和传播有关不实信息的任何单位或个人，有关部门将严肃追查，并依法追究其法律责任。后续，国家有关部门将根据市场情况，及时做好中央储备棉轮出工作，具体事项将通过正式渠道对外公布。（中国棉花协会）

The company also generated a record $49 billion in free cash flow and approved an additional $80 billion share repurchase authorization. NVIDIA guided for second-quarter revenue of $91 billion, plus or minus 2%. Executives See Multi-Trillion-Dollar AI Infrastructure Opportunity CEO Jensen Huang said AI infrastructure demand has "gone parabolic" as enterprises and cloud providers scale agentic AI workloads. He added that NVIDIA expects to grow faster than hyperscaler capital expenditures by expanding across sovereign AI, robotics, industrial AI, and enterprise deployments. Kress estimated global AI infrastructure spending could eventually reach $3 trillion to $4 trillion annually. At the same time, Huang said NVIDIA's upcoming Vera Rubin platform could open a roughly $200 billion CPU market tied to AI inference and orchestration workloads. NVIDIA continues to anchor the broader AI infrastructure rally, with analysts and portfolio managers pointing to accelerating hyperscaler spending, expanding AI compute demand, and long-term infrastructure buildouts, even as some investors raise concerns around valuation and margin sustainability. Analysts See NVIDIA As Central To AI Infrastructure Growth Futurum analyst Daniel Newman told CNBC on Thursday that NVIDIA continues to hold a dominant position in AI infrastructure despite rising competition and valuation concerns. He compared NVIDIA's current role to Apple during the previous technology cycle, describing the company as both a high-growth and relatively safe AI investment. He added that Futurum expects AI compute capacity to reach 190 gigawatts by 2030 alongside nearly $3 trillion in AI infrastructure spending. Similarly, Pence Capital Management CIO Dryden Pence told CNBC on Thursday that NVIDIA is foundational AI infrastructure, comparing the company's role to the transcontinental railroad during America's industrial expansion. Pence said Microsoft, Amazon, and Meta continue placing massive orders for AI infrastructure...

Palantir Technologies Challenges Pentagon Agency Over Analytics Contract marketscreener.com

Palantir is among the most controversial technology companies of the modern era. Its clients include US Immigration and Customs Enforcement (Ice), the US Army, police, intelligence, and security agencies in multiple European countries. The company also supplies technology to the Israeli military amid its genocide in Gaza. Despite mounting scrutiny over Palantir’s alleged links to human rights abuses and Israeli war crimes, several major media organisations have still partnered with the company – including German publishing giant Axel Springer, the new owner of the British newspaper The Telegraph. Axel Springer – which also owns Politico, Business Insider, Bild, and Welt – uses Palantir’s Foundry software across its media operations. Palantir has said that Axel Springer used Foundry to integrate data from its various publications and revenue streams, helping to build what the company described as "a more agile, data-driven publishing organisation" capable of responding more effectively to shifts in consumer behaviour and audience interests. According to Palantir, Foundry enables Axel Springer to gain "detailed insights into readership behaviour, advertising performance, and subscription models". New MEE newsletter: Jerusalem Dispatch Sign up to get the latest insights and analysis on Israel-Palestine, alongside Turkey Unpacked and other MEE newsletters But the relationship between Axel Springer and Palantir extends beyond technology partnerships. Between 2018 and 2019, Palantir chief executive Alexander Karp served on the publisher's supervisory board. Karp and Axel Springer's CEO, Mathias Döpfner, first met years earlier "at a party during Döpfner’s university days". The ties also appear to extend to Döpfner's son, Moritz, who reportedly worked as chief of staff at Thiel Capital, the investment firm founded by Palantir co-founder Peter Thiel. German business outlet Manager Magazin has reported that Thiel later invested in a venture capital fund established by Moritz...